Latest & greatest articles for bupropion

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on bupropion or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on bupropion and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for bupropion

61. Summaries for patients. Bupropion to prevent relapse in people who quit cigarette smoking. (Abstract)

Summaries for patients. Bupropion to prevent relapse in people who quit cigarette smoking. 11575280 2001 10 04 2017 11 16 0003-4819 135 6 2001 Sep 18 Annals of internal medicine Ann. Intern. Med. Summaries for patients. Bupropion to prevent relapse in people who quit cigarette smoking. S-40 eng Clinical Trial Journal Article Multicenter Study Randomized Controlled Trial United States Ann Intern Med 0372351 0003-4819 0 Delayed-Action Preparations 01ZG3TPX31 Bupropion AIM IM Adult Bupropion

2001 Annals of Internal Medicine Controlled trial quality: uncertain

62. Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs

Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs Halpern M T, Khan Z M, Young T L, Battista C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of sustained-release (SR) bupropion hydrochloride in health plan and work site smoking-cessation programmes. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of 100,000 employees

2000 NHS Economic Evaluation Database.

63. Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation Full Text available with Trip Pro

Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation Nielsen K, Fiore M C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Sustained-release bupropion, nicotine patch, or both for smoking cessation. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population consisted of smokers who were enrolled on a smoking cessation programme, the details of which were reported in a study published in 1999. Setting The study setting

2000 NHS Economic Evaluation Database.

64. New Drugs VI ? Rosiglitazone (Avandia®), Tolterodine (Detrol®), Bupropion (Wellbutrin SR®, Zyban®), Doxazosin (Cardura®)

New Drugs VI ? Rosiglitazone (Avandia®), Tolterodine (Detrol®), Bupropion (Wellbutrin SR®, Zyban®), Doxazosin (Cardura®) [44] New Drugs VII – Mirtazapine (Remeron®), Salmon-Calcitonin Nasal Spray (Miacalcin®), Gatifloxacin (Tequin®), Moxifloxacin | Therapeutics Initiative Independent Healthcare Evidence > > [44] New Drugs VII – Mirtazapine (Remeron®), Salmon-Calcitonin Nasal Spray (Miacalcin®), Gatifloxacin (Tequin®), Moxifloxacin Mirtazapine (Remeron ® ) Approved indication: “Symptomatic

2000 Therapeutics Letter

65. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. Full Text available with Trip Pro

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. Use of nicotine-replacement therapies and the antidepressant bupropion helps people stop smoking. We conducted a double-blind, placebo-controlled comparison of sustained-release bupropion (244 subjects), a nicotine patch (244 subjects), bupropion and a nicotine patch (245 subjects), and placebo (160 subjects) for smoking cessation. Smokers with clinical depression were excluded. Treatment (...) consisted of nine weeks of bupropion (150 mg a day for the first three days, and then 150 mg twice daily) or placebo, as well as eight weeks of nicotine-patch therapy (21 mg per day during weeks 2 through 7, 14 mg per day during week 8, and 7 mg per day during week 9) or placebo. The target day for quitting smoking was usually day 8.The abstinence rates at 12 months were 15.6 percent in the placebo group, as compared with 16.4 percent in the nicotine-patch group, 30.3 percent in the bupropion group (P

1999 NEJM Controlled trial quality: predicted high

66. A comparison of sustained-release bupropion and placebo for smoking cessation. Full Text available with Trip Pro

A comparison of sustained-release bupropion and placebo for smoking cessation. Trials of antidepressant medications for smoking cessation have had mixed results. We conducted a double-blind, placebo-controlled trial of a sustained-release form of bupropion for smoking cessation. We excluded smokers with current depression, but not those with a history of major depression. The 615 subjects were randomly assigned to receive placebo or bupropion at a dose of 100, 150, or 300 mg per day for seven (...) (a gain of 2.9 kg in the placebo group, 2.3 kg in 100-mg and 150-mg groups, and 1.5 kg in the 300-mg group; P= 0.02). No effects of treatment were observed on depression scores as measured serially by the Beck Depression Inventory. Thirty-seven subjects stopped treatment prematurely because of adverse events; the frequency was similar among all groups.A sustained-release form of bupropion was effective for smoking cessation and was accompanied by reduced weight gain and minimal side effects. Many

1997 NEJM Controlled trial quality: predicted high